All In Biotech

Drugs by condition

Drugs approved for stomach and esophageal cancer

Brand-name prescription drugs and biologics whose FDA label lists stomach and esophageal cancer as an approved use. Matched on the label phrases: "gastric", "esophageal".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

52

Still marketed, NDA or BLA

Drug classes

17

Novel drugs

19

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for stomach and esophageal cancer.

  • Oxderys (Doxorubicin Hydrochloride) · Avyxa Holdings Nov 9, 2026
  • Favlyxa (Fluorouracil) · Avyxa Holdings Feb 20, 2026
  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
  • E-Z-Disk (Barium Sulfate) · Bracco Aug 1, 2025
  • Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers Squibb Accelerated approvalDec 27, 2024

All approved drugs for stomach and esophageal cancer, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 275 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

HER2/neu Receptor Antagonist (6)

  • Herceptin Trastuzumab · Genentech · 1998
  • Kanjinti Trastuzumab-Anns · Amgen INC · 2019
  • Trazimera Trastuzumab-Qyyp · Pfizer INC · 2019
  • Ontruzant Trastuzumab-Dttb · Samsung Bioepis CO LTD · 2019
  • Herzuma Trastuzumab-Pkrb · Celltrion INC · 2018
  • Ogivri Trastuzumab-Dkst · Mylan Gmbh · 2017

Azole Antifungal (4)

  • Vfend Voriconazole · Pf Prism Cv · 2002
  • Vfend Voriconazole · Pf Prism Cv · 2003
  • Vfend Voriconazole · Pf Prism Cv · 2002
  • Diflucan Fluconazole · Pfizer · 1993

Programmed Death Receptor-1 Blocking Antibody (3)

  • Tevimbra Tislelizumab-Jsgr · Beigene · 2024
  • Opdivo Nivolumab · Bristol Myers Squibb · 2014
  • Keytruda Pembrolizumab · Merck Sharp Dohme · 2014

Microtubule Inhibitor (3)

Endoglycosidase (2)

  • Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
  • Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024

Proton Pump Inhibitor (2)

  • Prevacid Lansoprazole · Takeda Pharms USA · 1995
  • Prevacid Lansoprazole · Takeda Pharms USA · 2002

Prostaglandin E1 Analog (2)

  • Cytotec Misoprostol · Pfizer · 1988
  • Arthrotec Diclofenac Sodium, Misoprostol · Pfizer · 1997

Bispecific HER2-directed Antibody (1)

  • Ziihera Zanidatamab-Hrii · Jazz Pharms · 2024

Claudin 18.2-directed Cytolytic Antibody (1)

  • Vyloy Zolbetuximab-Clzb · Astellas · 2024

Programmed Death Ligand-1 Blocker (1)

  • Imfinzi Durvalumab · Astrazeneca Uk LTD · 2017

Nucleoside Analog Antiviral (1)

  • Lonsurf Tipiracil Hydrochloride, Trifluridine · Taiho Oncology · 2015

Vascular Endothelial Growth Factor Receptor 2 Antagonist (1)

  • Cyramza Ramucirumab · Eli Lilly and CO · 2014

CTLA-4-directed Blocking Antibody (1)

  • Yervoy Ipilimumab · Bristol Myers Squibb · 2011

Echinocandin Antifungal (1)

  • Eraxis Anidulafungin · Vicuron Holdings · 2006

Nucleoside Metabolic Inhibitor (1)

  • Favlyxa Fluorouracil · Avyxa Holdings · 2026

Radiographic Contrast Agent (1)

  • E-Z-Disk Barium Sulfate · Bracco · 2025

Class not listed in FDA's data (21)

Drugs in development for stomach and esophageal cancer

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • AdebrelimabSHR-8068, HRS -4642Phase 341 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors

  • CadonilimabAK104Phase 331 trials

    Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

  • SHR-A1811Trastuzumab RezetecanPhase 327 trials

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • SerplulimabHLX10, HLX43Phase 325 trials

    Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • I-DXdDS-7300a, MK-2400Phase 317 trials

    Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • TiragolumabMTIG7192A, RO7092284Phase 311 trials

    Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • ApatinibRIVO, RivoceranibPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma

  • CamrelizumabSHR-1210, CAMPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

  • QLC5508MHB088CPhase 39 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma

6 discontinued brand-name drugs whose label still names it

More on stomach and esophageal cancer: recruiting trials · published research

Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.